NEW YORK (GenomeWeb) – Within a large pharmacogenetic study ongoing at several Indiana institutions, researchers are aiming to tackle the issues that have kept personalized medicine approaches from reaching disadvantaged communities.

Earlier this month, Eskenazi Health, the Indiana Institute for Personalized Medicine (IIPM), the Indiana University School of Medicine, and the Regenstrief Institute announced the launch of a 6,000-patient prospective trial to study the impact of preemptive pharmacogenetic testing in a community healthcare setting.